Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr Platzbecker on First-Line ATRA/ATO in High-Risk Acute Promyelocytic Leukemia

July 31st 2024

Uwe Platzbecker, MD, discusses efficacy data with the combination of all-trans retinoic acid and arsenic trioxide in high-risk acute promyelocytic leukemia.

AYA ALL: Overview and Risk Stratification

July 31st 2024

Experts on acute lymphoblastic leukemia share their clinical experiences, describe high-risk features, and provide insights on risk stratification practices.

Clinical Scenario: A 23-Year-Old Male with AYA ALL

July 31st 2024

A panel of experts from Atrium Health Levine Cancer Institute present a patient case and provide an overview of adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL).

Asciminib Receives FDA Priority Review for Newly Diagnosed Ph+ CP-CML

July 30th 2024

The FDA has granted priority review to asciminib for newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

Dr Pollyea on the Mechanism of Revumenib in KMT2A-Rearranged R/R AML

July 30th 2024

Dan Pollyea, MD, MS, discusses the mechanism of action for the menin inhibitor revumenib in KMT2A-rearranged relapsed/refractory acute myeloid leukemia.

FDA Extends PDUFA Date for Revumenib in KMT2A-Rearranged Acute Leukemia

July 29th 2024

The FDA has extended the PDUFA date for the NDA seeking the approval of revumenib for patients with relapsed/refractory KMT2A-rearranged acute leukemia.

Blinatumomab Plus Consolidation Chemotherapy Extends OS in MRD– B-Cell Precursor ALL

July 24th 2024

Blinatumomab added to consolidation chemotherapy led to a significant OS benefit in MRD-negative B-cell precursor acute lymphoblastic leukemia.

Dr Watts on the Investigation of INCB057643 in Advanced Myelofibrosis and MPN

July 24th 2024

Justin M. Watts, MD, discusses the design and purpose of a phase 1 trial evaluating INCB057643 in myelofibrosis and other advanced myeloid neoplasms.

Iopofosine I 131 Meets MRR End Point in R/R Waldenström Macroglobulinemia

July 23rd 2024

Iopofosine I 131 generated a major response rate of 56.4% in patients with relapsed/refractory Waldenström macroglobulinemia.

FDA Accepts Resubmission of BLA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

July 23rd 2024

The FDA has accepted the resubmission of a BLA for remestemcel-L in pediatric steroid-refractory acute graft-vs-host-disease.

Phase 1b Study of Azacitidine, Venetoclax and Revumenib in Newly Diagnosed Older Adults with NPM1 Mutated or KMT2A Rearranged AML: Interim Results of Dose Escalation from the Beat AML Consortium

July 23rd 2024

A Phase 1b study (NCT03013998) to determine the safety and recommended dose of Revumenib combined with Aza/Ven in patients with newly diagnosed AML ≥ 60 years old with NPM1mut or KMT2Ar and who are not candidates or do not wish to pursue intensive induction therapy.

Five-Year Follow-Up Data Confirm Long-Term Benefits of Olutasidenib in R/R IDH1+ AML

July 22nd 2024

Justin M. Watts, MD, discusses 5-year efficacy and safety data for olutasidenib in IDH1-mutant, relapsed/refractory AML.

Dr Shadman on the Evaluation of Zanbrutinib Plus Sonrotoclax in Treatment-Naive CLL

July 22nd 2024

Mazyar Shadman, MD, MPH, discusses the rationale for combining sonrotoclax plus zanubrutinib for treatment-naive chronic lymphocytic leukemia.

Dr Eckfeldt on the Implications of Improved MRD Testing in AML

July 19th 2024

Craig Eckfeldt, MD, PhD, discusses how improved minimal residual disease testing methods have impacted the acute myeloid leukemia treatment paradigm.

Dr Juckett on the Evolving Treatment Paradigm in Relapsed/Refractory AML

July 18th 2024

Mark Juckett, MD, discusses ways the treatment paradigm has changed for patients with relapsed/refractory acute myeloid leukemia.

Dr Hughes on the Safety of Asciminib in Ph+ CP-CML

July 18th 2024

Timothy Hughes, MD, MBBS, FRACP, FRCPA, on safety data for asciminib in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia.

Clinical Scenario and Perspectives on the Evolving Treatment Landscape in GVHD

July 17th 2024

Dr. Hannah Choe discusses a clinical scenario of a patient with GVHD who has progressed after multiple lines of treatment. She explores how the availability of CSF-1R inhibitors could fit into the evolving treatment landscape for managing this difficult-to-treat patient population. Dr. Choe provides her perspectives on the potential role and clinical implications of targeting this pathway as an emerging therapeutic approach for GVHD.

AGAVE-201 Investigating Axatilimab In Recurrent of Refractory cGVHD

July 17th 2024

Dr. Hannah Choe reviews data from the AGAVE-201 trial investigating the CSF-1R inhibitor axatilimab, including efficacy, safety, and clinical implications of these data for patients with recurrent or refractory chronic GVHD.

Odronextamab Elicits Durable Responses in Heavily Pretreated R/R Follicular Lymphoma

July 17th 2024

Odronextamab elicited deep, durable responses in heavily pretreated patients with relapsed/refractory follicular lymphoma.

Brentuximab Vedotin Triplet Improves Survival Over R2 Across Key R/R DLBCL Subgroups

July 17th 2024

Brentuximab vedotin plus lenalidomide/rituximab (R2) provided a superior overall survival benefit vs R2 alone in relapsed/refractory DLBCL.

x